Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025

Rhea-AI Summary

Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis through biomarkers and AI algorithms, has announced its participation in the Planet MicroCap Showcase: VEGAS 2025. The presentation is scheduled for April 23, 2025, at 12:30 PM ET, where CEO Brent Ness will discuss the company and its recent value-driving initiatives. In conjunction with the event, the company has released an updated investor presentation available on their investor relations website.

BROOMFIELD, Colo., April 23, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 12:30 PM ET.

Brent Ness, Chief Executive Officer of Aclarion, will be presenting on the Company and recent value-driving initiatives.

In conjunction with the event, Aclarion has published its updated investor presentation, which can be found on its website at https://investors.aclarion.com/.

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.  For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:

Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com

Media Contact:

Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com

FAQ

When is Aclarion (ACON) presenting at Planet MicroCap Showcase 2025?

Aclarion is presenting on Wednesday, April 23, 2025 at 12:30 PM ET at the Planet MicroCap Showcase: VEGAS 2025.

Where can I find Aclarion's (ACON) latest investor presentation?

Aclarion's updated investor presentation is available on their investor relations website at https://investors.aclarion.com/

What technology does Aclarion (ACON) use for chronic low back pain diagnosis?

Aclarion uses biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain.

Who will be presenting for Aclarion (ACON) at the Planet MicroCap Showcase?

Brent Ness, Chief Executive Officer of Aclarion, will be presenting on the company and recent value-driving initiatives.